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Formicamycin biosynthesis involves a unique reductive ring 
contraction† 
Zhiwei Qin, ‡a Rebecca Devine, ‡b Thomas J Booth,a Elliot H E Farrar,c Matthew N Grayson,c 
Matthew I Hutchingsa,b* and Barrie Wilkinsona* 
Fasamycin natural products are biosynthetic precursors of the formicamycins. Both groups of compounds are polyketide 
natural products that exhibit potent antibacterial activity despite displaying different three-dimensional topologies. We 
show here that transformation of fasamycin into formicamycin metabolites requires two gene products and occurs via a 
novel two-step ring expansion-ring contraction pathway. Deletion of forX, encoding a flavin dependent monooxygenase, 
abolished formicamycin production and leads to accumulation of fasamycin E. Deletion of the adjacent gene forY, encoding 
a flavin dependent oxidoreductase, also abolished formicamycin biosynthesis and led to the accumulation of new lactone 
metabolites that represent Baeyer-Villiger oxidation products of the fasamycins. These results identify ForX as a Baeyer-
Villiger monooxygenase capable of dearomatizing ring C of the fasamycins. Through in vivo cross feeding and biomimetic 
semi-synthesis experiments we showed that these lactone products represent biosynthetic intermediates that are reduced 
to formicamycins in a unique reductive ring contraction reaction catalyzed by ForY.
Introduction 
    Bacterial aromatic polyketide natural products comprise an 
extensive family of biosynthetically related molecules that 
encompass great structural variety and often display potent 
biological activity.1 They include several important clinical agents, for 
example the tetracycline antibiotics and anthracycline antineoplastic 
drugs. The carbon skeletons of aromatic polyketides are invariably 
derived from the function of dissociated, type II polyketide synthases 
(PKSs), and additional structural diversity is introduced by tailoring 
enzymes following polyketide biosynthesis. 2 , 3  Such post-PKS 
transformations include acylation, alkylation, glycosylation and 
halogenation, as well as redox changes. Further structural complexity 
can be introduced via carbon-carbon bond cleavage and 
rearrangements in processes commonly catalyzed by oxidative 
enzymes. Illustrative examples include the reactions catalyzed by 
flavin-dependent Baeyer-Villiger (BV) monooxygenase enzymes 4 
during the biosynthesis of the jadomycins, 5  gilvocarcins5 and 
chartreusins6 amongst others. 
    We recently described the formicamycins, poly-halogenated 
tridecaketides that are co-products, along with the fasamycins, of the 
Streptomyces formicae KY5 for biosynthetic gene cluster (BGC; Fig. 1 
and S1) encoding a type II PKS. 7  The fasamycins exhibit potent 
antibacterial activity and congeners were first reported from 
heterologous expression of environmental DNA and were encoded 
by a clone expressing a type II PKS BGC, but no co-produced 
formicamycins were reported.8 Despite their common biosynthetic 
origin and carbon backbone connectivity, the fasamycins and 
formicamycins have very different three-dimensional structures as 
determined from NOESY NMR, ECD spectroscopy and computational 
modelling.7 Moreover, the formicamycins displayed more potent 
antibacterial activity and a barrier for the selection of resistant 
isolates. 
    Mutational analysis of the formicamycin (for) BGC identified 
a single flavin dependent halogenase (ForV) that can 
presumably catalyze multiple halogenation events.7 Deletion of 
forV abolished the production of all halogenated congeners and 
the ∆forV mutant produced only a single compound fasamycin 
C 1 but no formicamycins (Fig. 2b); the deletion could be 
complemented by ectopic expression of forV.7 This suggests a 
gatekeeper function for ForV, meaning the enzymes which 
convert fasamysins to formicamycins operate on halogenated 
intermediates, confirming that the fasamycins are biosynthetic 
precursors of the formicamycins. Structural comparison of the 
two skeletons indicates that unusual biosynthetic 
transformations are required to enable their interconversion, 
involving a dearomatization of fasamycin ring C via a formal 
tautomerization and two-electron reduction, plus the 
introduction of a tertiary hydroxyl group at C10. This suggests 
the requirement for a reductive enzyme in addition to a 
monooxygenase. These intriguing biosynthetic observations, in 
concert with their antibacterial properties, prompted us to 
study the biosynthetic steps linking the two compound families.       
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Results 
Bioinformatics analysis 
    The for BGC was sequenced previously7 and comparison to the 
originally reported fasamycin BGC8 did not identify any additional 
genes obviously responsible for formicamycin biosynthesis. 
However, comparison to a for-like BGC identified in a 140 kbp region 
of the Streptomyces kanamyceticus genome that is syntenic with S. 
formicae KY5 (Genbank ID LIQU00000000.1), identified a set of four 
grouped genes forX-forAA which are not present in S. kanamyceticus 
(Fig. 3). A similar observation was made when we compared the for 
BGC to the recently reported BGC encoding production of accramycin 
A, a new fasamycin congener.9 Three of these gene products (ForY, 
ForZ and ForAA) show high homology to sequences from 
Actinomadura species, suggesting they may have been acquired via 
horizontal gene transfer. The gene product ForX is a putative flavin-
dependent monooxygenase, and both sequence homology and 
predicted structural homology10 searches indicated the most closely 
related characterized homologue is aklavinone 12-hydroxylase 
(RdmE) (Table 1), a Group A flavin-dependent monooxygenase.11,12 
Group A monooxygenases are reported to catalyze hydroxylation or 
sulfoxidation. Sequence alignments of ForX and RdmE showed an 
overall identity of 41%, with three noticeable regions of low 
homology between residues 70-119, 212-245 and 365-393 in the 
RdmE structure (31HG), corresponding to the substrate binding 
pocket. Structural homology searches predicted ForY to be a TIM 
beta/alpha barrel oxidoreductase (Table 1), homologues of which 
typically utilize flavin cofactors to perform redox 
chemistry.13,14,15,16,17 The genes forZ and forAA encode a MarR family 
transcriptional regulator and an MFS family transporter respectively. 
 
 
 
Fig. 1 Chemical skeletons of fasamycins (1-3) and formicamycins (4-16) isolated from S. formicae KY5, and Baeyer-Villiger lactone 
intermediates (17-21) isolated from the S. formicae ΔforY mutant in this study (for detailed substituent variations including 
halogenation or O-methylation, see Fig. S1). The 2D NMR structure determination of 18 is shown by COSY (bold), NOESY (red double-
head arrow), and selected HMBC (blue single-head arrow) correlations respectively. R1-4 = H or Cl; R5 = H or CH3. 
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Mutational analysis identifies a two-step biosynthetic 
transformation 
    Guided by our bioinformatic observations we made individual 
in-frame deletions in forX and forY using Cas9 mediated gene 
editing. The resulting mutants failed to produce formicamycins, but 
this was restored after ectopic expression of the deleted genes (Fig. 
S2). Despite producing no formicamycins, S. formicae ΔforX 
accumulated the previously isolated fasamycin E (3) (Fig. 2c) which 
was confirmed by isolation and NMR characterization (Fig. S3 and 
S4). This is consistent with the hypothesis that ForX catalyzes an 
oxidation required for formicamycin biosynthesis, and that it 
functions on halogenated fasamycin substrates. In contrast, S. 
formicae ΔforY accumulated six new compounds 17-22 (Fig. 2d). 
After scaling up fermentation (4 L) and solvent extraction, a small 
amount of each of the congeners 17-21 (5-13 mg) was isolated and 
subjected to structure determination using 2D NMR and MS. 
Compound 22 could not be isolated but analytical MS and UV data 
were consistent with it being a related biosynthetic congener. We 
first determined the structure of 18 because high-resolution ESI-MS 
predicted a molecular formula of C28H22O8Cl2 indicating one more 
oxygen atom compared with 3, but with a distinct UV spectrum 
(λmax 248 and 300 nm vs. 249, 289, 355, and 415 nm for 3) 
indicating a major structural change. 1D and 2D NMR experiments 
showed a striking low- to high-field chemical shift for the carbonyl 
group (C11) in comparison to 3, in addition to the appearance of 
new methylene and lactone carbonyl moieties. Based on these 
observations, and other connectivity, we assigned the structure of 
18 as a Baeyer-Villiger lactone derivative of 3 (Fig. 1). Further 
analysis identified 19 as the C5-O-methyl congener of 18, and 17 as 
lacking a chlorine atom at C2 when compared to 18. The remaining 
two congeners 20 and 21 were determined to contain further 
variations in chlorination and O-methylation (Fig. S1).  
    These results are consistent with a two-step ring expansion-
ring contraction pathway for the conversion of fasamycins into 
formicamycins with ForX catalyzing a Baeyer-Villiger reaction on 
fasamycin substrates, and ForY catalyzing the two-electron 
reduction of the Baeyer-Villiger intermediates with concomitant 
ring contraction via hydride addition at C19. To provide support for 
our hypothesis we attempted to express and isolate both proteins 
for biochemical analysis but, despite extensive experimentation, we 
were unable to obtain soluble protein. Undeterred, we instead 
utilized biomimetic chemical synthesis to investigate the 
biosynthetic pathway (see below), but first verified the 
intermediacy of the isolated lactones through a cross feeding 
experiment. Exogenous 18 (isolated from S. formicae ΔforY) was 
added to growing cultures of the S. formicae ΔforX biosynthetic 
mutant and after nine days incubation LCMS analysis of an ethyl 
Name Accession number Top hit  % coverage % identity 
ForX WP_049717083.1 
Hypothetical protein, Streptomyces 
caatingaensis 
94 50 
ForY WP_089326038.1 
LLM class flavin-dependent oxidoreductase, 
Actinomadura meyerae 
87 60 
ForZ WP_121435158.1 
MarR transcriptional regulator, Actinomadura 
pelletieri 
84 42 
ForAA WP_122199503.1 
DHA2 family efflux MFS transporter permease 
subunit, Actinomadura sp. NEAU-Ht49 
96 57 
Table 1 Characteristics of for BGC gene products discussed in this study. 
 
Fig. 2 Mutational analysis of the tailoring enzyme encoding genes 
involved in formicamycin biosynthesis. Deletion of forX abolishes 
the production of formicamycins but leads to accumulation of 
fasamycin E (3). Deletion of forY abolishes the production of 
formicamycins and leads to accumulation of six biosynthetic 
intermediates (17-22). Reconstituted HPLC traces (UV = 285 nm) 
showing: (a) S. formicae wild type; (b) S. formicae ΔforV (for 
details see7); (c) S. formicae ΔforX; (d) S. formicae ΔforY. 
0
300000
600000
m
AU
(2
85
 n
m
)
0
1000000
2000000
m
AU
(2
85
 n
m
)
0
100000
200000
6 7 8 9 10 11 12
m
AU
(2
85
 n
m
)
Retention time / min
4
1
5
11
9 10
7
13
2 3
6
8
&
12
17
18
22
20
19
21
a
0
2000000
4000000
m
AU
(2
85
 n
m
) b
c
d
ARTICLE Journal Name 
4  |  J. Name. , 2012, 00,  1-3  This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
acetate extract of the culture broth indicated that 18 was converted 
 
 
 
Fig. 3 Comparison of the fasamycin/formicamycin biosynthetic gene clusters (top) and the alternate pathways for each step of the 
proposed two-step ring expansion-contraction mechanism of formicamycin biosynthesis from fasamycin E (3) (bottom) 
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efficiently into the previously isolated formicamycin congeners 5, 8, 
9, and 13 plus the O-methylated lactone 19 (Fig. S5). This is consistent 
with 18 being a direct biosynthetic intermediate of the 
formicamycins and a putative substrate of ForY. 
Biomimetic semi-synthesis of the formicamycins 
    To mimic the ForY catalyzed biosynthetic transformation we 
subjected an analytical sample (~0.1 mg) of the lactone 19 to sodium 
borohydride reduction (Fig. 4a). This yielded three new products with 
a mass increase of 2 Da, plus an additional compound with a mass 
decrease of 14 Da (Fig. 4b). Notably, and in contrast to 19, the 
products 23 and 24 (0.97:1 ratio) displayed formicamycin like UV 
spectra (Fig. 4c). The reaction was then scaled up (using 4 mg of 19) 
and the products 23 (~0.4 mg) and 24 (~0.2 mg) were purified by 
HPLC. 2D NMR experiments indicated that these both contained the 
formicamycin ring structure, consistent with the proposed reduction 
and ring contraction mechanism (Fig. S59). Chemical shift 
comparisons to biosynthetic congeners, in addition to 1D NOE data, 
confirmed that 23 corresponds to the natural (10RS,19RS) 
diastereoisomer and 24 to the (10RS,19SR) diastereoisomer. The 
product 25 (~0.4 mg) was isolated with 24 (1:1 mixture) and NMR 
analysis clearly showed 25 to be a lactone in which the C10-C19 
double bond was reduced but for which rearrangement via ring 
contraction had not occurred. NMR analysis then showed that 25 
corresponds to a single diastereoisomer and the NOESY spectrum 
showed a strong correlation between H-10 and H-19 indicating the 
(10RS,19RS) configuration. The NMR and MS date for the remaining 
-14 Da component is consistent with deoxygenation at C11 as shown 
for 26 (Fig. 4). The biomimetic reaction was then repeated using 
lactone congener 17 (5.4 mg) as the starting material and analysis of 
the products showed an almost identical outcome to that for sodium 
borohydride reduction of 19 (Fig. S6). 
To better understand their stereochemical composition, we 
determined the [α]D2 0 values of 23 and 24 to be +68° and -73° 
respectively indicating that the reductive transformation had 
occurred with induction of chirality, most probably due to the Sa-
atropoisomeric axis of the C6-C7 bond deriving from the fasamycin 
precursors. The fixed atropoisomeric axis was confirmed by 
determining the rotational energy barrier for the C6-C7 bond of 
fasamycin C (1) using DFT calculations (see Supporting Information). 
This yielded a value of ΔE = 156.1 kJ mol-1 indicating that little to no 
axial rotation should be expected about this bond, with the 
frequency of rotation on the order of years.18 The positive sign of the 
[α]D2 0 for 23 is consistent with all previous naturally occurring 
formicamycins which have [α]D2 0 values in the range +162° to +469°. 
Unfortunately, we had not isolated the formicamycin congener 23 in 
our previous work and therefore could not assign the enantiomeric 
excess of this molecule based on optical rotation comparison to a 
standard. While the isolated sample of 23 is a mixture of two 
enantiomers at C10/C19, given the essentially fixed atropoisomeric 
axis at C6-C7, these two molecules should be diastereotopic with 
respect to each other. However, the 1H NMR spectrum for this 
sample did not indicate split chemical shifts at any position and the 
initial HPLC analysis showed a single peak. We thus repeated the 
chromatographic analysis using the higher resolving power of UPLC, 
and varied the elution conditions, and were able to resolve the 
isolated sample of 23 into two peaks of the same mass and with the 
same UV spectra (Fig. 5) consistent with their diastereotopic 
relationship. Integration of these two peaks indicated a 
diastereomeric excess (%de) of 41.3%. The equivalent analysis of 
 
Fig. 4 Biomimetic reduction of the biosynthetic intermediate 19 and isolated products. (b) HPLC-UV (285 nm) trace of the initial 
reaction products from (a); (c) UV spectra of the reaction substrate (19), two main products of interest (23 and 24), plus formicamycin 
B (5) as a standard for comparison. 
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isolated 24 indicated a %de of 40.5%. Mixing the isolated samples of 
23 and 24 and repeating the UPLC analysis confirmed the presence 
of 4 peaks, whereas reanalysis of this mixture using the original HPLC 
conditions showed only 2 peaks, consistent with no change to the 
sample following purification. UPLC analysis of formicamycins 
isolated from S. formicae KY5 indicated all congeners were single 
diastereoisomers. 
 
Conclusions 
    The two-step pathway described here explains the significant 
structural changes that must occur to transform the almost flat 
fasamycin skeleton into the twisted chair-like configuration of the 
formicamycins. The dearomatization of aromatic systems as a 
prelude to structural diversification has been described for several 
natural products including, for example, recent mutational analysis 
of the agnestins19 and cryptosporioptides20 where deletion of genes 
encoding putative Baeyer-Villigerases led to accumulation of the 
anticipated aromatic precursors. For the Baeyer-Villiger activity of 
ForX, two alternative mechanisms can be invoked for reaction 
between the fasamycin substrate, reduced flavin cofactor and 
oxygen. In the first pathway (Pathway I) the peroxyflavin species acts 
as an electrophile to catalyze oxygen introduction as a tertiary 
hydroxyl group at C10 following deprotonation of the adjacent 
phenol (Fig. 3). Subsequent rearrangement then occurs with bond 
migration and protonation at C20. Alternatively, (Pathway II) ForX 
could first induce tautomerization of ring C, possibly through 
substrate binding, followed by donation of a proton from the 
peroxyflavin cofactor to the resulting C9 ketone generating an 
oxonium intermediate. The resulting flavoperoxy anion can then act 
as a nucleophile in a canonical BV-like reaction to generate the 
observed lactone intermediate. The tautomerization required in the 
first step of Pathway II has precedent in the reaction of 
dehydrorabelomycin and congeners during the biosynthesis of 
gilvocarcins and jadomycins.5 However, we favor Pathway I which is 
reminiscent of that by which a nucleophilic chloride ion is converted 
into a highly reactive electrophilic species via the intermediacy of 
hypochlorous acid by flavin-dependent halogenases. 21  This is 
consistent with our observation that ForX groups phylogenetically 
with the Group A monooxygenases that typically catalyze 
hydroxylation. 
We propose that ForY then acts as a flavin-dependent reductase 
catalyzing two-electron reduction of the intermediate lactone. This 
reaction most likely proceeds via 1,4-conjugate attack of a hydride 
ion at C19 to form the corresponding enolate 27. Collapse of the 
enolate can then occur with formation of the new C9-C10 sigma 
bond and formation of an epoxide intermediate with subsequent 
rearrangement to yield the C10-tertiary hydroxyl group with overall 
ring contraction in a process reminiscent of a Favorskii reaction.  This 
pathway (Fig. 3 ) is consistent with the side products observed in the 
sodium borohydride biomimetic reduction, and with the steric 
requirements for orbital overlap during C9-C10 bond formation. 
Although rare in nature a Favorskii-type reaction has been 
demonstrated to occur during biosynthesis of the polyketide natural 
product enterocin produced by Streptomyces maritimus. 22  This 
pathway involves oxidative activation of the preceding intermediate 
via a dual 4-electron oxidation. The reaction is catalyzed by the 
unique flavin dependent monooxygenase EncM which utilizes a 
flavin-N5-oxide, rather than a peroxyflavin intermediate, to catalyze 
substrate oxidation and trigger a Favorskii-type reaction23. Oxidation 
promotes further aldol and heterocylization reactions which are also 
mediated by EncM.22,23 Based on the outcome of careful stable isotope 
labeling experiments, a Favorskii-like reaction has also been 
proposed to occur during biosynthesis of the fungal polyketide 
metabolite roussoellatide.24 
The production of a single steric isomer during the biosynthesis 
of formicamycins and the lack of any conjugate reduction side 
products as are observed during the sodium borohydride biomimetic 
reduction of isolated lactone biosynthetic intermediates indicates 
that ForY must control both the stereochemical progress of this 
reaction and limit alternative reaction coordinates. As described, the 
proposed reductive ring contraction catalyzed by ForY is unique in 
polyketide biosynthesis and future work will seek to understand this 
novel biochemical process in greater detail. A search of all available 
microbial genome sequences did not identify any additional close 
homologues. Further searches using MultiGeneBlast 25  with 
sequences for the minimal PKS genes plus forX, with and without 
forY, failed to identify any additional candidate BGCs that might 
encode pathways that operate as described here suggesting that this 
pathway is unique to formicamycin biosynthesis. 
Materials and methods 
For details regarding experimental procedures, microbiology 
and molecular biology procedures, spectroscopic data, see the 
ESI. 
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Fig. 5 Reconstituted UPLC-UV (285 nm) analysis for the isolated 
reduction products 23 (a), 24 (b), and a mixture of the isolated 
products (c) indicating the diastereomeric composition of these 
samples. 
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